ABSTRACT

Objective: This study was undertaken to formulate a floating drug delivery system of theophylline hydrochloride using different concentrations of a chosen polymer and then investigate how polymer concentration affects buoyancy and drug release properties of the tablets.

Methods: Hydroxypropyl methylcellulose (HPMC) at different concentration levels of 15% (F1), 20% (F2) and 30% (F3) was used to form the three formulation batches of floating tablets. Wet granulation method was used for the granule preparation while Sodium bicarbonate and citric acid were used as the gas generating agent. The physical properties of the granules and the floating tablets were evaluated. Also determined were the formulation batches of floating tablets. Wet granulation method was used for the granule preparation while Sodium bicarbonate and citric acid were used as the gas generating agent. The physical properties of the granules and the floating tablets were evaluated. Also determined were the

Results: The result showed that polymer (HPMC) concentration significantly (p>0.05) increased swelling index and improved floating lag time, it had no significant effect on the total floating time. Percentage drug release at the end of 8 h was 100%, 98.2% and 96.13% for formulation F1, F2 and F3, respectively. All three formulations followed the Higuchi drug release kinetics model and the mechanism of drug release was the non-Fickian diffusion with exponents of 0.46, 0.51 and 0.56 for the respective batch.

Conclusion: Batch F3 gave a better-controlled drug release and floating properties in comparison to batch F1 and F2 thus Polymer concentration influenced the onset of floating and controlled the release of Theophylline.

Keywords: Theophylline, Buoyancy, Swelling index, Floating tablets, Gastric residence time

INTRODUCTION

Oral delivery is the most popular route of drug administration due to its versatility, ease of administration and patient compliance [1]. Drugs with short half-lives and that are easily absorbed from the gastrointestinal tract (GIT) are, however, eliminated quickly from systemic circulation after oral administration. To achieve and maintain the concentration of these types of drugs within the effective therapeutic range, it is often necessary to frequently administer the drug with resultant fluctuation levels in the plasma [2]. To avoid this limitation, the development of oral modified (sustained) release formulations is an attempt to release the drug slowly into the gastrointestinal tract and maintain an effective drug concentration in systemic circulation for a long time [3].

After oral administration, sustained release dosage forms are retained in the gastrointestinal tract, releasing the drug in a controlled manner, so that its absorption sites in the tract are continuously supplied. These drug delivery systems nevertheless suffer mainly from two physiological events: (i) the unpredictable short gastric emptying time and (ii) the brief gastric retention time. These can result in incomplete drug release from the dosage form in the absorption region (stomach or upper part of the small intestine), leading to diminished efficacy of administered dose [3]. Gastric emptying of dosage forms is an extremely variable process, thus being able to influence the emptying time can be a valuable asset for dosage forms that can reside in the stomach for a longer period of time than the conventional ones [4]. Many studies have been performed on gastro retentive delivery, an approach to achieve sustained release dosage forms of drugs having prolonged gastric residence time and this technique helps to improve site-specific targeting, increased solubility, better absorption and overall bioavailability of some poorly soluble of drugs such as theophylline, domperidone [5].

Theophylline is a methylxanthine derivative that is very effective in the treatment of chronic bronchial asthma and bronchospastic reaction. It has a narrow therapeutic concentration range (from 10-20 µg/ml) with a short half-life, which necessitates frequent dosing with conventional dosage forms [6].

Fig. 1: Chemical structure of theophylline

The toxicity of theophylline usually appears at a concentration above 20 µg/ml and the fluctuations in its serum concentration can result in variability in the clinical response. Therefore, there is an obvious therapeutic need for a sustained release dosage form of theophylline, which will be able to maintain its therapeutic serum levels throughout 24 h following a once or twice daily dose administration [7]. Although several works have formulated theophylline floating delivery, many as directly compressible tablets, capsules, microbeads and as suspension, this original work was aimed at preparing sustained release effervescent floating tablet matrix of theophylline after wet granulation method and then determine the effect of HPMC concentration on ideal buoyancy and drug release [6, 8, 9].
MATERIALS AND METHODS

Materials

Anhydrous Theophylline hydrochloride was purchased as a pure drug from Sigma-Aldrich, UK. Other excipients used were: HPMC (Hopkins and Williams Ltd, Stanheat Essex, England), Sodium bicarbonate, Stearic acid (BDH chemicals Poole, England) and citric acid (Philip Harris Ltd, Shenstone, England), magnesium stearate and talc obtained from (Shermen chemical Ltd, Sunderland and Sandy, England). Also, 95 % ethanol (Analar grade) was used.

Method

Preparation of granules

The granules were prepared using the wet granulation method. Three batches of granules were prepared using the different concentrations of HPMC as the polymer. Batch 1 consisted of 10% polymer concentration (F1), a second batch (F2) and a third one (F3) consisted of 20% and 30% polymer concentration respectively. For batch 1 the ingredients (theophylline, sodium bicarbonate and citric acid) were weighed accurately and thoroughly mixed in a porcelain mortar. Granulation was done with a mixture of required HPMC in 95 % ethanol added to the powder mix in the mortar to form a wet mass. The wet mass was passed through a 2 mm sieve and the resulting granules dried in a conventional hot air oven at 60 °C for 2 h. The dried granules were then passed through a 1 mm sieve to obtain finer granules of uniform size. The same procedure was repeated for batch 2 and 3.

Evaluation of theophylline granules

Flow rate and angle of repose

Angle of repose was determined using the fixed funnel method. A clean dry funnel was kept upright in a retort stand at a height 10 cm above a paper placed in a flat horizontal surface. The aperture of the funnel was blocked and 10 g of powder sample was poured into the funnel. Then the funnel was opened to release the powder onto the paper to form a conical heap. The height of the heap was measured by using a ruler and the diameter of the cone was also measured. The experiment was repeated three times for each batch of granules and the average was calculated. Angle of repose was calculated by using the equation (1). The flow rate of the granules was determined by recording the time taken for the 10 g of granules from each batch to flow through the fixed funnel suspended from the retort stand. Triplicate values were determined.

\[
\tan \theta = \frac{h}{r} \quad (1)
\]

Where,

\( h \) - height of heap and \( r \) - radius of the base of the powder

Table 1: Composition of theophylline floating tablet

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theophylline (mg)</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>HPMC (%)</td>
<td>15</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>Sodium bicarbonate (%)</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Citric acid (%)</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Stearic acid (%)</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Magnesium Stearate (%)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Talc (%)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Granule density (\( \rho_g \))

\[
\rho_g = \frac{d_50(W_5)}{W_5(W_2-W_1)} \quad (6)
\]

Where,

\( d_s \) is the density of non-solvent (Xylene), \( W_s \) is the weight of granule sample, \( W_5 \) is the weight of pycnometer+solvent and \( W_2 \) is the weight of pycnometer+sample+solvent

Granule porosity and packing fraction of the granules

The porosity and packing fraction of each batch of granules were determined using the equations below:

\[
Packing\ fraction\ (PF) = \frac{BD}{GD} \quad (7)
\]

\[
Granule\ porosity = [1-PF] \quad (8)
\]

Compression of theophylline tablets

The prepared granules were lubricated with 5 % stearic acid, 1 % magnesium stearate and 1 % talc, and compressed into tablets using a single punch tabletting press fitted with 12.5 mm flat-faced punches (Cadmach, India) at a constant compression force of 15kN.

Evaluation of theophylline floating tablets

Weight uniformity test

Twenty (20) tablets were randomly selected from each batch and individually weighed using an electronic balance (Ohaus, Galaxy). The mean, standard deviation and coefficient of variation were calculated.

Crushing strength and friability

The crushing strength of the tablets was determined using the Monsanto hardness tester (Rolex, Chandigarh). Ten tablets from each batch were randomly selected and tested and the average calculated. The friability of 5 tablets was measured in a Roche friability apparatus (UNID 056830 Campbell Electronic, Mumbai).
India). The tablets were dusted and weighed (W0) and before being placed in the friabilator, which was then operated at a speed of 25 rpm for 4 min. Then the tablets were removed from the chamber dusted and reweighed (W1). The friability was then calculated using the equation below:

\[ Friability = \left(1 - \frac{W_1}{W_0}\right) \times 100 \]  

Where, W0 is the initial weight of tablets before the test, W1 is the final weight of tablets after the test.

**Thickness and diameter**

The thickness of each of 10 randomly selected tablets was determined using the micrometer screw gauge (KFW Scientific Industries Ambala Cantt, India) and the average thickness was calculated.

The diameter of each of 10 tablets from each batch was randomly selected and their individual diameter was determined using the micrometer screw gauge (KFW Scientific Industries Ambala Cantt, India) and the average diameter was calculated.

**Tablet porosity**: The tablet porosity was calculated using the Equation below;

\[ \text{Tablet porosity} = 1 - \frac{m}{\rho} \times 100 \]  

Where, m is mean weight of tablets, ρ is particle density, r is mean tablet radius and h is tablet thickness.

**Swelling index**

One tablet from each batch was weighed before placing them in a Petri dish containing 0.1N HCl. At 30 minute intervals, the swollen tablets were taken out and weighed after mopping off the fluid medium from the swollen tablets using a blotting paper. The swelling index of the tablets was then measured and diluted up to 10 ml with 0.1N HCl and then analyzed spectrophotometrically at 271 nm using 0.1N HCl as blank. The concentration of theophylline was then obtained by using the standard calibration curve of theophylline.

**In vitro buoyancy studies**

One tablet from each formulation was placed in 250 ml beaker containing 0.1N HCl. The time taken by the tablet to move from the bottom of the beaker to the top and float was noted and recorded as the floating lag time. The time for which the tablet remained floating on the surface was noted and recorded as total floating time. The determination was carried out in triplicates and the average calculated.

**Standard calibration curve of theophylline in 0.1N HCl**

A 50 mg quantity of theophylline powder was dissolved in 30 ml of 0.1N HCl. The resultant solution was transferred to 50 ml volumetric flask and made up to volume with 0.1N HCl. Serial dilutions of 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml and 12 µg/ml were prepared, and their absorbances were read in a UV-spectrophotometer (UNICO-spectrophotometer, UV-2100 PC, Shanghai Instrument Co., China) at a wavelength of 271 nm. Graphs of absorbance versus concentration were plotted to obtain the calibration curves of theophylline in 0.1N HCl.

**Absolute drug content of theophylline tablets**

Ten pre-weighed tablets from each batch were crushed in a mortar. A powdered quantity equivalent to 200 mg was weighed out and dissolved in 100 ml of 0.1N HCl in a volumetric flask. The solution was filtered using a Whatman filter paper no.2, 0.1 ml of the filtrate was then measured and diluted up to 10 ml with 0.1N HCl and then analyzed spectrophotometrically at 271 nm using 0.1N HCl as blank. The concentration of theophylline was then obtained by using the standard calibration curve of theophylline.

**In vitro drug release study of theophylline floating tablets**

Drug release study was carried out according to USP I (basket) method. The dissolution studies were conducted with dissolution apparatus (RZC-63, China). The dissolution medium was 900 ml of 0.1N HCl maintained at a temperature of 36±0.5 °C. The agitation of the medium was maintained at 50 rpm. 10 ml aliquots were withdrawn at 30 min interval up to 8 h and replaced each time with an equivalent of 10 ml of the dissolution medium maintained at the same temperature. The withdrawn samples were filtered through a Whatman filter paper no.2, diluted appropriately and then analyzed spectrophotometrically at a wavelength of 271 nm using UNICO-spectrophotometer (UV-2100PC Shanghai Instrument Co. Ltd., China) and cumulative percentage drug release was calculated.

**In vitro kinetic release studies of theophylline floating matrix tablets**

Data obtained from dissolution studies were subjected to release kinetics evaluation to determine which model most appropriately describes it.

The model with the highest correlation coefficient (\(R^2\)) was considered to be the best fit for the designated kinetic release.

**Mechanism of drug release from theophylline sustained release matrix tablets**

The likely mechanism of drug release was determined by plotting the percentage drug release fitted into Korsemeyer-Peppas model equation.

**Statistical analysis**

All experiments were carried out in triplicates and the results expressed as mean±SD. The data obtained were subjected to analysis of variance (ANOVA) and differences between means were considered significant at P<0.05.

**RESULTS AND DISCUSSION**

<table>
<thead>
<tr>
<th>Table 2: Micromeritic and flow properties of theophylline granules</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Formulation code</strong></td>
</tr>
<tr>
<td>F1</td>
</tr>
<tr>
<td>F2</td>
</tr>
<tr>
<td>F3</td>
</tr>
</tbody>
</table>

**Table 3: Physical properties of theophylline floating tablet matrix**

<table>
<thead>
<tr>
<th><strong>Batch code</strong></th>
<th><strong>Weight (g) n=20</strong></th>
<th><strong>Thickness (mm) n=10</strong></th>
<th><strong>Diameter (mm) n=10</strong></th>
<th><strong>Hardness (kg/cm²) n=10</strong></th>
<th><strong>Friability (%) n=5</strong></th>
<th><strong>Drug content (%)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>0.41±0.01 (2.2%)</td>
<td>3.1±0.11</td>
<td>12.23±0.09</td>
<td>4.34±0.32</td>
<td>0.95</td>
<td>99.50</td>
</tr>
<tr>
<td>F2</td>
<td>0.41±0.01 (2.4%)</td>
<td>3.1±0.04</td>
<td>12.23±0.14</td>
<td>4.44±0.32</td>
<td>0.93</td>
<td>99.80</td>
</tr>
<tr>
<td>F3</td>
<td>0.41±0.01 (2.5%)</td>
<td>3.2±0.08</td>
<td>12.21±0.12</td>
<td>4.52±0.31</td>
<td>0.86</td>
<td>98.80</td>
</tr>
</tbody>
</table>

Result is presented as mean±standard deviation and number of times (n) =3.
The result of the physical properties of tablets produced with the different proportions of HPMC is presented in the table 3. From the result, the crushing strength of the tablets was in the range of 4.34 to 4.52 kgf, the weight variations of the tablets of all the formulation was less than 5%. The friability of all the formulations was in the range of 0.86% to 0.95%. Tablet thickness and diameter was in range of 3.13 mm to 3.22 mm and 12.21 mm to 12.23 mm respectively. Absolute drug content of all the formulations were found to be in range of 95.50% to 99.80%. Floating lag time ranged from 52 seconds to 123 seconds. Total floating time was>24 h for batch F1, F2 and F3.

Weight uniformity test is a pharmacoepid test which ensures consistency of dosage units during compression. The weight uniformity test indicated no significant difference (P>0.05) in the weights of tablets from batch F1 to F3 and hence conformed to the specification of the British Pharmacopoeia [12].

Although there was no significant difference (P>0.05) amongst the tablet dimensions (thickness and diameter), tablet hardness was between 4.34 kgf/f and 4.54 kgf/f for all formulation. Tablet hardness affects parameters like tablet disintegration, dissolution as well as the buoyancy properties of the tablet [13]. There was no significant difference (P>0.05) in the tablet hardness in the different proportions of the polymer used. However hardness exerts an effect on the floating of the tablets. This is because hardness influences the compaction of substances in the tablets, the higher the hardness, the higher the compaction. A higher compaction decreases the porosity of the tablet matrix causing a retardation of solvent penetration into the tablet core [15]. In fact Kiatissak et al., (2007) had reported that tablets with hardness of 8 kg/cm² showed no floating capability.

**Table 4: Other properties of theophylline granules and floating tablets**

<table>
<thead>
<tr>
<th>Batch code</th>
<th>Granule density (g/ml)</th>
<th>Granule porosity (%)</th>
<th>Packing fraction</th>
<th>Tablet porosity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>1.33±0.01</td>
<td>74.3±0.01</td>
<td>0.26±0.01</td>
<td>58.20</td>
</tr>
<tr>
<td>F2</td>
<td>1.28±0.01</td>
<td>73.4±0.01</td>
<td>0.27±0.01</td>
<td>56.60</td>
</tr>
<tr>
<td>F3</td>
<td>1.10±0.00</td>
<td>72.7±0.00</td>
<td>0.28±0.00</td>
<td>51.10</td>
</tr>
</tbody>
</table>

The friability of all the formulations was in the range of 0.86 % to 0.96%. The test of friability measures the ability of the tablet to withstand abrasion during packing, handling and shipping. The normal limits for tablet friability is less than 1% [12]. From the result of the study, the friability loss for all formulation was found to be within this stipulated limit. There was an observed decrease in tablet friability as the proportion of the polymer increases. The increased resistance of the matrix to fracture and abrasion as the polymer concentration increased could be attributed to the formation of more solid bonds [16].

<table>
<thead>
<tr>
<th>Drug content</th>
<th>Batch 1</th>
<th>Batch 2</th>
<th>Batch 3</th>
<th>Batch 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/ml</td>
<td>1.10±0.00</td>
<td>1.28±0.01</td>
<td>73.4±0.01</td>
<td>72.7±0.00</td>
</tr>
<tr>
<td>%</td>
<td>0.26±0.01</td>
<td>0.27±0.01</td>
<td>0.28±0.00</td>
<td>0.28±0.00</td>
</tr>
</tbody>
</table>

The results of drug content for batch1, batch 2 and batch 3 were 99.50 %, 98.80 % and 99.8 % respectively. These results are within the official limits [17], indicating proper mixing and processing of all the three batches.

**Other properties of theophylline granules and floating tablets**
The result of granule density, packing fraction, granule porosity and tablet porosity of theophylline floating tablets is shown in table 3. From the result, the granule density ranged from 1.10 g/ml to 1.33 g/ml, packing fraction ranged from 3.66 to 3.89; granule porosity is in the range of 72.70 % to 74.30 %, while tablet porosity ranged from 51.10 % to 58.20 %

There was no significant difference (p<0.05) in the granule density, granule porosity and packing fraction with an increase in polymer concentration. There was an observed decrease in porosity from granule to tablet; this is due to the compression of the granules during the tabletting process which results in a reduction in porosity [18]. There was an observed increase in packing fraction with a decrease in granule porosity.

**Swelling index and in vitro buoyancy studies**
The swelling index study measures the hydration ability of the tablet. It influences tablet buoyancy, swelling behavior and drug release kinetics [23]. The result (fig. 3) shows that the swelling index increased with an increase in polymer concentration and contact time with the dissolution medium. The hydrophilic nature of the HPMC may have contributed to this observation with a sustained index after about 4 hours likely signaling point of complete polymer hydration. From the result, the floating lag time ranges from 52 seconds to 123 seconds whereas the total floating time was>24 h for each batch, and during this time, the size of the swollen matrix gel
reduced because of disintegration and erosion. It was also observed that some of the gas generated from the tablet on hydration in the dissolution medium, was retained within the gel, thus decreasing the density of the tablet below 1.2 g/cm$^3$, and conferring buoyancy to the tablet. This was seen in tablets not disintegrating. Previous studies showed that tablets with a density greater than 1.004 g/cm$^3$ could not float on gastric fluid. A floating system is better with a shorter floating lag time (as seen in batch F3) so that the tablet may not attach to the lower part of the stomach impeding buoyancy, and suffering the physiological consequence of gastric emptying [1].

### Table 5: Effect of HPMC concentration on the buoyancy property of the floating tablet

<table>
<thead>
<tr>
<th>Batch code</th>
<th>Floating lag time (FLT) (s) n=3</th>
<th>Total floating time (TFT) (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>123±4.71</td>
<td>&gt;24</td>
</tr>
<tr>
<td>F2</td>
<td>77±4.98</td>
<td>&gt;24</td>
</tr>
<tr>
<td>F3</td>
<td>52±2.05</td>
<td>&gt;24</td>
</tr>
</tbody>
</table>

The increase in the concentration of the polymer did not have any significant effect ($p>0.05$) on the total floating time. However, the different proportions of the HPMC in the different batches had a significant effect ($p<0.05$) on the floating lag time as increased concentration of polymer resulted in decreased floating lag time. One possible reason could be related to the swelling index study, whereby the tablet with a higher proportion of the polymer exhibited more polymer hydration per time with the high swelling index value at any time compared to the tablet having lower polymer concentration. The rapid hydration of the polymer results in the formation of a gelatinous layer when in an aqueous medium. This gelatinous layer reduces the escape of generated gas from the tablet matrix thereby decreasing the density of the tablet which leads to the floating of the tablet within a short period of time [24].

### In vitro dissolution studies

The release profile revealed that an increase in polymer concentration reduces the percentage of drug released. The increase in hydrophilic polymer proportion results in increase viscosity of the tablet matrix gel layer after hydration of the polymer as well as the formation of a gel layer with a longer diffusional path [25]. This phenomenon could explain the decrease in effective diffusion of the drug out of the gel and a consequent reduction in the rate of drug release.

The percentage drug release at the end of 8 h was 100%, 98.2% and 96.13% for formulation batches F1, F2 and F3 respectively. The drug release was sustained for 8 h for all the batches. However, there was an observed faster onset of drug release initially with a subsequent decrease in the release rate with time. Hydrophilicity of the polymer promotes the wetting of the tablet matrix with a burst release of the drug at the initial stage of hydration, then controlled release follows due to the viscous gel mass of the tablet polymer retarding drug release [24].

### Table 6: Release kinetics of theophylline floating tablet

<table>
<thead>
<tr>
<th>Batch code</th>
<th>Zero order</th>
<th>First order</th>
<th>Higuchi model</th>
<th>Korsemeyer model</th>
<th>Diffusion exponent(n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>0.856</td>
<td>0.507</td>
<td>0.975</td>
<td>0.976</td>
<td>0.46</td>
</tr>
<tr>
<td>F2</td>
<td>0.864</td>
<td>0.278</td>
<td>0.973</td>
<td>0.975</td>
<td>0.51</td>
</tr>
<tr>
<td>F3</td>
<td>0.883</td>
<td>0.205</td>
<td>0.972</td>
<td>0.974</td>
<td>0.56</td>
</tr>
</tbody>
</table>

**Release kinetics and mechanism of release of theophylline floating tablets**

The result of the in vitro release kinetics and mechanism of release of theophylline floating tablets is presented in table 6. The regression values indicate that all the batches (F1, F2 and F3) followed Higuchi model of release kinetics. Thus the drug release is directly proportional to the square root of time, indicating that the drug release is diffusion controlled. Furthermore, the drug release data were fitted into the Korsemeyer-Peppas model (table 6) and it revealed that the diffusion
mechanism involved in the drug release was non-Fickian diffusion type for F2 and F3 but fickian for F1. It has been reported that the release mechanism of drugs from HPMC matrix is by non-Fickian diffusion or anomalous transport involving both diffusion and matrix erosion [26]. Also, there was an observed increase in the value of the diffusion exponent (n) as the concentration of polymer increases.

**Release parameters of theophylline floating tablet**

The time is taken for 50 % and 90 % of theophylline to be released ($t_{50}$ and $t_{90}$) respectively were adopted to characterize the release of theophylline from the tablets. From the result presented in table 7, there was an observed increased in the time taken for 50 % and 90 % of theophylline to be released with an increased in the polymer concentration. At high polymer content, the gel layer becomes stronger and more viscous bringing about a higher resistance to diffusion and matrix erosion. This consequently retards drug release thus prolonging the time taken for 50 % and 90 % of the drug to be released respectively [25].

Also, higher polymer concentration increases the diffusion path length of the drug due to the formation of a greater amount of gel which retards drug release from the formulation.

### Table 7: Release parameters of theophylline floating tablets

<table>
<thead>
<tr>
<th>Batch code</th>
<th>$t_{50}$ (h)</th>
<th>$t_{90}$ (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>1.9</td>
<td>5.6</td>
</tr>
<tr>
<td>F2</td>
<td>2.2</td>
<td>6.0</td>
</tr>
<tr>
<td>F3</td>
<td>2.5</td>
<td>6.2</td>
</tr>
</tbody>
</table>

**CONCLUSION**

In conclusion, polymer concentration resulted in no significant difference (p>0.05) in granule density, granule porosity, packing fraction and tablet porosity. The increase in HPMC concentration from 15 % to 30 % did not have a significant effect (p>0.05) on the total floating time of the tablets as all tablet batches remained floated for more than 24 h. However, the floating lag time (FLT) and swelling index were significantly affected (p<0.05) with higher HPMC concentration causing a reduction in the floating lag time but an increase in the swelling index of the tablet. An increase in the polymer concentration reduced drug release rate and followed the Higuchi model. While Batches F2 and F3 followed non-Fickian mechanism of release, F1 was in line with the Fickian type. Finally, Batch F3, containing 30 % of HPMC gave the best drug delivery and floating properties in comparison to the other batches, as it possessed the shortest floating lag time as well as gave a better control of the rate of drug release.

**AUTHORS CONTRIBUTIONS**

Akpabio E designed the work, supervised Sunday N to carry out the laboratory work with guidance from Uwah T. Effiong D wrote the article. All authors critically revised and approved the work for publication.

**FUNDING**

Nil

**CONFLICT OF INTERESTS**

None

**REFERENCES**

